查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2147364

人工智慧心臟超音波：預測、競爭動態和能力限制驅動人工智慧的應用，2024-2035 年

Cardiovascular Ultrasound and Echo AI: Forecasts, Competitive Dynamics, and the Capacity Squeeze Driving AI Adoption, 2024-2035
出版日期: | 出版商: Marketstrat, Inc. | 英文 26 Pages | 訂單完成後即時交付

價格

報告摘要

這份 Marketstrat® 重點報告分析了 2024 年至 2035 年全球超音波系統中的心血管超音波和心臟超音波圖。該報告估算了循環系統領域的市場規模，分析了其成長要素，並描繪了每個工作流程控制點的超音波心臟檢查 AI 競爭格局。

預計競爭優勢正從超音波設備的影像品質轉向超音波工作流程的管理。心臟影像的需求成長速度超過了設備和超音波技師的供應速度，這種產能限制使得人工智慧驅動的影像擷取和測量自動化成為必然之選。

需要解答的關鍵問題

  • 到 2035 年，心臟病學為何會成為超音波應用最大的領域？哪些因素將推動這項成長？
  • 供應商何時應該根據臨床應用領域而不是終端市場來制定每個手術的計劃？
  • 隨著 OEM 捆綁銷售產品的增加，Echo AI 的哪些控制點能夠帶來永續的盈利？
  • 考慮到 2026 年循環系統領域的支付壓力，人工智慧超音波心動圖的保險報銷進展如何？

市場概覽

所有數據均基於Marketstrat的超音波核心模型計算。循環系統領域的市場規模由診斷影像覆蓋區域（按臨床適應症分類）和預算分配區域（按手術終端市場分類）共同計算。這兩者回答的是不同的問題，不應簡單地相加。循環系統領域將在期末成為最大的適應症領域，其成長速度將超過整個生態系統。

主要市場趨勢

  • 1. 結構性心臟病促使超音波心臟檢查數量增加。經導管瓣膜治療需要在篩檢、手術和追蹤期間進行超音波心臟檢查。
  • 2. 軟體正在鞏固其在高階市場的地位。隨著 3D/4D 經食道超音波心動圖 (TEE)、心內超音波心動圖和超音波心動圖融合技術的發展，高階市場的重點正在轉向手術流程。
  • 3.超音波技師短缺是一個結構性問題。在無法確保足夠人員配備的檢查室中，他們正在對經驗不足的操作人員進行培訓，並採用遠端品質控制（teleQA）進行遠端評估。
  • 4. 獎勵機制是決策支援型人工智慧應用的關鍵因素。雖然基礎超音波心動圖檢查的獎勵機制已經足夠完善，但超音波心動圖人工智慧的獎勵機制仍在透過第三類編碼進行製定中。

目錄

第1章摘要整理

  • 三個數字凸顯了這一機遇
  • 由此可以得出的一個見解是
  • 本報告的主要內容

第2章 心血管超音波市場定義

  • 臨床應用展望：值得關注的市場
  • 按流程分類的終端市場觀點：更快更清晰的觀點。

第3章 市場規模及預測：成長要素分析

  • 四大成長要素
  • 循環系統領域在生態系中的位置

第4章：驅動需求與擴散的因素

  • 結構性心臟病促使超音波心動圖的需求不斷上升。
  • 術中影像技術是推動需求的關鍵因素。
  • 勞動力短缺是一個結構性問題，這也是推動人工智慧應用的原因。
  • 人口趨勢支撐著長期需求基礎。
  • 產能不足：需求超過了設備和人員的供應。

第5章：Echo AI 的競爭格局

  • 了解各控制點的市場結構
  • 控制點以及每家公司在每個控制點的位置。
  • OEM在循環系統領域的定位
  • 人工智慧相關資金將流向何處？

第6章：經濟學與償還

  • 超音波檢查的基礎研究已經相當成熟。
  • 針對迴聲人工智慧的保險報銷正在增加。
  • 心臟CT領域值得關注的先例。
  • 然而，到 2026 年，支付壓力將會增加。

第7章 戰略架構：成熟與擴散

  • 技術成熟度（M-TEM）
  • 擴散和影響（T-DIC）

第8章 區域趨勢：美國與歐洲

  • 美國
  • 歐洲

第9章：影響、風險與建議措施

  • 基於玩家類型的洞察
  • 本文的主要風險
  • 建議的因應措施（未來 12-18 個月）

第10章：近期趨勢和值得關注的徵兆

第11章：調查方法

第12章 參考公司及概要

  • 參考公司
  • 概要
Product Code: MINTF-02105-UF03

Report Overview

This Marketstrat® Focus Report analyzes cardiovascular ultrasound and echocardiography within the global ultrasound ecosystem from 2024 through 2035. It sizes the cardiology pool, decomposes its growth, and maps the echo-AI competitive set by workflow control point.

Our view is that advantage is moving from echo-hardware fidelity toward control of the echo workflow. Cardiac-imaging demand is outrunning both equipment supply and the sonographer workforce, and that capacity squeeze makes AI-guided acquisition and measurement automation an operating requirement.

Key Questions Answered

  • Why does cardiology become the largest ultrasound application pool by 2035, and what drives the increment?
  • When should vendors plan against the clinical-application cut rather than the procedural end-market cut?
  • Which echo-AI control points hold durable economics as OEM bundling rises?
  • How far has echo-AI reimbursement progressed against 2026 cardiology payment pressure?

Market Snapshot

All figures reconcile to the Marketstrat ultrasound core model. Cardiology is sized by what is imaged (the clinical-application cut) and by where the budget sits (the procedural end-market cut); the two answer different questions and should not be summed. Cardiology ends the period as the largest application pool and grows ahead of the ecosystem overall.

Key Market Trends

  • 1. Structural heart pulls echo volume upward. Transcatheter valve therapy needs echo at screening, during the procedure and at follow-up.
  • 2. Software now defends the premium cart. 3D/4D TEE, intracardiac echo and echo-fluoro fusion shift the premium toward procedural workflow.
  • 3. The sonographer gap is structural. Labs that cannot hire enough staff buy guidance for less-expert operators and tele-QA for remote review.
  • 4. Reimbursement gates decision-support AI. The base echo study is well paid, while echo-AI payment is still emerging through Category III coding.

Competitive Structure

Cardiology is the densest AI vendor cluster in ultrasound. The report positions OEMs such as GE HealthCare, Philips and Mindray alongside independents including Us2.ai, UltraSight, Ultromics, Echo IQ and HeartLab, by control point and enterprise readiness, and asks who becomes embedded in routine echo workflow before the category consolidates.

What's Inside

Sizing and growth bridge: Two cardiology cuts and four demand drivers.

Echo-AI competitive set: Control-point mapping, OEM positioning and AI capability mix.

Reimbursement: Echo and echo-AI coding, the cardiac-CT precedent and 2026 payment pressure.

Markintel® frameworks and outlook: M-TEM maturity, T-DIC diffusion and impact, US and European detail, risks and a 12–18-month action agenda.

Who Should Read This Report

  • Ultrasound and cardiovascular OEM strategy teams
  • Echo-AI founders weighing OEM partnerships
  • Investors and corporate-development teams in cardiac imaging
  • Echo lab and cardiology service-line leaders planning capital and staffing

Why This Report

The report keeps capital demand and the software opportunity separate, treats the workforce gap as a modeled adoption driver, and dates post-baseline developments so readers can tell the modeled baseline from the refresh.

Table of Contents

1. EXECUTIVE SUMMARY

  • THREE NUMBERS THAT FRAME THE OPPORTUNITY
  • THE ONE IMPLICATION
  • WHAT THIS REPORT COVERS

2. DEFINING THE CARDIOVASCULAR-ULTRASOUND POOL

  • 2.1 THE CLINICAL-APPLICATION CUT: THE HEADLINE POOL
  • 2.2 THE PROCEDURAL END-MARKET CUT: A FASTER, DISTINCT LENS

3. SIZING AND FORECAST: DECOMPOSING THE GROWTH

  • 3.1 THE FOUR DRIVERS
  • 3.2 HOW THE CARDIOLOGY POOL SITS INSIDE THE ECOSYSTEM

4. DEMAND AND ADOPTION DRIVERS

  • 4.1 STRUCTURAL HEART PULLS ECHO DEMAND UPWARD
  • 4.2 INTRAPROCEDURAL IMAGING IS A PREMIUM ATTACH ENGINE
  • 4.3 THE WORKFORCE GAP IS STRUCTURAL, AND IT PULLS AI IN
  • 4.4 DEMOGRAPHICS UNDERWRITE THE LONG-RANGE BASE
  • 4.5 THE CAPACITY SQUEEZE: DEMAND IS OUTRUNNING BOTH EQUIPMENT AND LABOR

5. THE ECHO-AI COMPETITIVE SET

  • 5.1 MAPPING THE LANDSCAPE BY CONTROL POINT
  • 5.2 THE CONTROL POINTS, AND WHO IS POSITIONED
  • 5.3 OEM CARDIOVASCULAR POSITIONING
  • 5.4 WHERE THE AI DOLLARS MIGRATE

6. ECONOMICS AND REIMBURSEMENT

  • 6.1 THE BASE ECHO STUDY IS WELL ESTABLISHED
  • 6.2 ECHO-AI REIMBURSEMENT IS EMERGING
  • 6.3 A CARDIAC-CT PRECEDENT WORTH WATCHING
  • 6.4 BUT 2026 BRINGS PAYMENT PRESSURE

7. STRATEGIC FRAMEWORKS: MATURITY AND DIFFUSION

  • 7.1 TECHNOLOGY MATURITY (M-TEM)
  • 7.2 DIFFUSION AND IMPACT (T-DIC)

8. REGIONAL COLOR: UNITED STATES AND EUROPE

  • 8.1 UNITED STATES
  • 8.2 EUROPE

9. IMPLICATIONS, RISKS, AND RECOMMENDED ACTIONS

  • 9.1 IMPLICATIONS BY PLAYER TYPE
  • 9.2 KEY RISKS TO THE THESIS
  • 9.3 RECOMMENDED ACTIONS (NEXT 12–18 MONTHS)

10. DATED DEVELOPMENTS AND SIGNALS TO WATCH

11. METHODOLOGY

12. COMPANIES REFERENCED AND ABSTRACT

  • 12.1 COMPANIES REFERENCED
  • 12.2 ABSTRACT

List of Exhibits

  • EXHIBIT 1: GLOBAL ULTRASOUND CLINICAL APPLICATION MIX, 2024A VS 2035E
  • EXHIBIT 2: CARDIOLOGY / ECHO ECOSYSTEM-REVENUE GROWTH BRIDGE, 2024A → 2035E
  • EXHIBIT 3: THE SONOGRAPHER GAP AS AN ECHO-AI ADOPTION DRIVER: DEMAND-VS-SUPPLY DIVERGENCE AND THE MODELED OPERATING-MODEL SHIFT
  • EXHIBIT 4: THE CAPACITY SQUEEZE: INDEXED GROWTH OF STRUCTURAL-HEART PROCEDURE VOLUME VS CARDIOVASCULAR- ULTRASOUND EQUIPMENT VS US SONOGRAPHER SUPPLY
  • EXHIBIT 5: ECHO-AI VENDOR LANDSCAPE: WHO OWNS WHICH CONTROL POINT IN THE CARDIAC WORKFLOW
  • EXHIBIT 6: WHERE ULTRASOUND-AI DOLLARS MIGRATE, 2024A → 2035E: CAPABILITY MIX OF CORE AI RECURRING REVENUE
  • EXHIBIT 7: ECHO-AI TECHNOLOGY TRANSITIONS RANKED BY DIFFUSION AND IMPACT (T-DIC), WITH MATURITY STAGE